参芪口服液与阿托伐他汀在高脂血症大鼠中的有益相互作用:药代与药效研究
该研究在高脂饮食诱导的高脂血症大鼠中观察参芪口服液(SQ)与阿托伐他汀(ATV)联用的药效与药代相互作用,发现联用可协同降脂并改善肝脏组织学,SQ显著提高ATV代谢物体内暴露并调节转运体与代谢酶,提示联用时可能需要调整ATV剂量。
要点
- SQ与ATV联用可协同降脂并改善肝脏组织学。
- SQ显著增加ATV代谢物o-ATV和p-ATV的Cmax与AUC0-t。
- SQ调节肠道转运体及肝脏代谢酶,联用时或需调整ATV剂量。
核心结论
- SQ与ATV通过调节药物转运体和代谢酶在降脂与保肝方面产生协同作用。
- 研究提示联用期间可能需要调整ATV剂量,为合理联用提供科学依据。
研究设计与样本
- 高脂饮食诱导高脂血症大鼠,按血清总胆固醇水平采用随机区组设计分组。
- 设模型组、ATV 10 mg/kg组、SQ 0.68、1.68、3.38 g/kg组及联合组,治疗4周。
主要发现
- 联合治疗显著降低血清脂质水平并改善肝脏组织学,细胞结构更有序、脂滴积累减少。
- SQ使o-ATV的Cmax和AUC0-t分别提高97.02%和119.01%,p-ATV分别提高73.22%和63.39%(均P<0.05)。
- SQ下调空肠Bcrp和Mrp2及回肠Oatp2b1、Bcrp、Mrp2表达,上调肝脏Oatp1b2和CYP3A2表达(均P<0.05)。
- SQ增强CYP2C11和CYP3A2酶活性,表现为奥美拉唑AUC0-∞(P<0.01)和咪达唑仑AUC0-t(P<0.05)显著降低。
- tangshenoside I、lobetyolin和ononin可促进CYP3A2 mRNA表达(P<0.05)。
关键数值与推荐
- ATV剂量为10 mg/kg,SQ剂量为0.68、1.68、3.38 g/kg,治疗4周。
- o-ATV的Cmax和AUC0-t分别提高97.02%和119.01%,p-ATV分别提高73.22%和63.39%(均P<0.05)。
- 奥美拉唑AUC0-∞显著降低(P<0.01),咪达唑仑AUC0-t显著降低(P<0.05)。
临床怎么用
- 联用SQ与ATV时应关注ATV代谢物暴露增加,必要时考虑调整ATV剂量。
- SQ可能通过抑制肠道Bcrp/Mrp2和诱导肝脏CYP3A2影响ATV代谢,联用时需监测疗效与安全性。
局限性
- 研究仅在大鼠高脂血症模型中进行,结论外推至人体需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the pharmacodynamic and pharmacokinetic interactions between Shenqi Oral Liquid (SQ) and atorvastatin (ATV) in hyperlipidemic rats, explore the impact of SQ on ATV-related transporters and metabolic enzymes, the potential implications for the safety and rationality of their combined administration based on pharmacodynamic, pharmacokinetic, transporter, and metabolic enzyme data. METHODS: Hyperlipidemic rats were induced using a high-fat diet and randomized according to serum total cholesterol levels using a randomized block design into model, ATV (10 mg/kg), SQ (0.68, 1.68, 3.38 g/kg), and combination groups, and treated for 4 weeks. Serum lipid profiles, liver histopathological changes, pharmacokinetic parameters of ATV, mRNA expression levels of transporters (including Bcrp, Mrp2, etc.) and metabolic enzymes (CYP2C11, CYP3A2), enzyme activities, as well as the effects of SQ's active ingredients were assessed using quantitative PCR, cocktail probe assays, and primary hepatocyte studies. RESULTS: The combination therapy significantly reduced serum lipid levels and improved liver histology, as evidenced by a more organized cellular structure and reduced accumulation of lipid droplets. SQ significantly increased systemic exposure of ATV metabolites, elevating the maximum plasma concentration (Cmax) and area under the curve from time 0 to time t (AUC0-t) of o-ATV by 97.02% and 119.01%, and of p-ATV by 73.22% and 63.39%, respectively (all P<0.05). SQ downregulated the expressions of Bcrp and Mrp2 in the jejunum and Oatp2b1, Bcrp, and Mrp2 in the ileum, while upregulating Oatp1b2 and CYP3A2 in the liver (all P<0.05). Additionally, it enhanced the enzymatic activities of CYP2C11 and CYP3A2, as shown by significantly reduced AUC0-∞ of omeprazole (P<0.01) and AUC0-t of midazolam (P<0.05). Notably, tangshenoside I, lobetyolin, and ononin were found to promote CYP3A2 mRNA expression (P<0.05). CONCLUSIONS: SQ synergizes with ATV in lipid regulation and hepatoprotection through modulation of drug transporters and metabolic enzymes. These findings suggest that dose adjustment of ATV may be necessary during combination therapy, thereby providing a scientific basis for the rational co-administration of these agents.
引用
- Hu XR, Li ML, Liu WK, et al. Beneficial Herb-Drug Interaction of Shenqi Oral Liquid on Atorvastatin: A Pharmacokinetic and Pharmacodynamic Investigation in Rats with Hyperlipidemia. Chin J Integr Med. 2026. PMID: 41989500. doi:10.1007/s11655-026-4031-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。